Latham & Watkins advised Harmony Biosciences, while Paul Hastings LLP advised J.P. Morgan as the sole book-running manager in the offering.Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY)…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
